1. Home
  2. PDFS vs IMNM Comparison

PDFS vs IMNM Comparison

Compare PDFS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDF Solutions Inc.

PDFS

PDF Solutions Inc.

N/A

Current Price

$42.33

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$20.21

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PDFS
IMNM
Founded
1992
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.5B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
PDFS
IMNM
Price
$42.33
$20.21
Analyst Decision
Buy
Strong Buy
Analyst Count
8
17
Target Price
★ $60.75
$35.33
AVG Volume (30 Days)
563.0K
★ 1.4M
Earning Date
11-05-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 51.40
EPS
★ 0.22
N/A
Revenue
N/A
★ $6,941,000.00
Revenue This Year
$20.46
N/A
Revenue Next Year
$20.66
$18,803.97
P/E Ratio
$178.00
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$23.55
$14.64
52 Week High
$71.69
$30.06

Technical Indicators

Market Signals
Indicator
PDFS
IMNM
Relative Strength Index (RSI) 43.83 53.83
Support Level $39.79 $19.47
Resistance Level $48.78 $23.48
Average True Range (ATR) 2.60 0.90
MACD -0.20 0.47
Stochastic Oscillator 32.75 96.83

Price Performance

Historical Comparison
PDFS
IMNM

About PDFS PDF Solutions Inc.

PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: